Osteoporosis Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

Description

Osteoporosis, a debilitating bone disease affecting millions worldwide, is on the rise, with 10 million individuals identified in the US alone. As per recent market reports, the global revenue from the osteoporosis drugs market reached US$ 13.9 billion in 2024, and it is projected to reach an estimated valuation of US$ 18 billion by the end of 2031.

Advancements in Diagnosis and Treatment

Recent years have witnessed substantial advancements in osteoporosis therapy choices and diagnostic techniques. Despite these improvements and the increasing incidence of the disease, substantial portions of the population remain untreated. Osteoporosis is associated with an elevated risk of fragility fractures, leading to increased morbidity and, in severe cases, mortality, especially in hip and vertebrae fractures.

Current Treatment Options

Current treatment options for osteoporosis include bisphosphonates, denosumab, raloxifene, teriparatide, and the recently introduced Romosozumab. These drugs have been developed over the past three decades and are effective. However, concerns about rare adverse effects, persistent comorbidities, and the short-term efficacy of anti-resorptive drugs have contributed to growing treatment gaps.

Promising Future Therapies

The future of osteoporosis treatment looks promising, with advancements in molecular comprehension of bone metabolism and bioengineering paving the way for novel treatment paradigms. Antibody therapeutics, stem cell therapies, and gene therapies are on the horizon, offering new hope for osteoporosis patients.

Skin Disorders and Osteoporosis

Interestingly, research indicates a link between skin disorders, which affect one-third of the global population, and osteoporosis. Inflammation and cytokine patterns are common denominators in both conditions. Dermatological patients exposed to glucocorticoids and immunosuppressants face an increased risk of osteoporosis. Understanding shared pathophysiology pathways between skin conditions and osteoporosis may lead to innovative treatment modalities.

Challenges and Concerns

The market for osteoporosis drugs is not without its challenges. Product recalls and adverse effects associated with current treatment modalities have raised concerns. While drugs like Denosumab are generally well tolerated, they are not without side effects, including musculoskeletal pain, hypersensitivity, dermatological responses, infections, hypercholesterolemia, and rare occurrences of atypical femoral fractures and jaw osteonecrosis.

Booming U.S. Market

The U.S. market for osteoporosis drugs is experiencing remarkable growth, driven by growing healthcare investments and rising public awareness. Government investments in healthcare, especially in developed economies like North America, play a pivotal role in driving market growth.

Germany's Lucrative Market

Germany, with key manufacturers within its borders, is poised for significant sales revenue growth in the osteoporosis drugs market.

Japan's Emerging Prominence

Japan's focus on the development of reimbursement guidelines to close the treatment gap for osteoporosis is making it an emerging prominent market. The inclusion of continual secondary fracture management examinations ensures timely evaluation and therapy for individuals who have experienced hip fractures.

Competitive Landscape

To maintain market competitiveness, industry firms are collaborating and investing in research and development to introduce innovative products.

Key Companies in the Osteoporosis Drugs Market

Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
Merck & Co, Inc.
Novartis AG
Amgen, Inc.
Novo Nordisk A/S
Actavis plc
Pfizer, Inc.
GlaxoSmithKline plc
Teva Pharmaceutical Industries Ltd.
Enzene Biosciences Ltd.
Theramex

The global osteoporosis drugs market is evolving, driven by advancements in diagnosis, treatment options, and promising therapies on the horizon. As governments invest in healthcare, awareness grows, and innovative solutions emerge, the market is expected to continue its upward trajectory.

Key Segments Covered in Global Osteoporosis Drugs Market Research

Drug:

Bisphosphonates
Parathyroid Hormone Therapy Drugs
Calcitonin
Selective Oestrogen Receptors Modulators (SERMs)
RANK Ligand Inhibitors

Distribution Channel:

Retail Pharmacies
Hospital Pharmacies
Online Sales

Region:

North America
Latin America
Europe
South Asia
East Asia
Oceania
Middle East & Africa

1. Executive Summary

1.1. Global Osteoporosis Drugs Market Snapshot
1.2. Future Projections
1.3. Key Market Trends
1.4. Regional Snapshot, by Value, 2023
1.5. Analyst Recommendations

2. Market Overview

2.1. Market Definitions and Segmentations
2.2. Market Dynamics
- 2.2.1. Drivers
- 2.2.2. Restraints
- 2.2.3. Market Opportunities
2.3. Value Chain Analysis
2.4. Porter's Five Forces Analysis
2.5. COVID-19 Impact Analysis
- 2.5.1. Supply
- 2.5.2. Demand
2.6. Impact of Ukraine-Russia Conflict
2.7. Economic Overview
- 2.7.1. World Economic Projections
2.8. PESTLE Analysis

3. Global Osteoporosis Drugs Market Outlook, 2018 - 2031

3.1. Global Osteoporosis Drugs Market Outlook, by Drug, Value (US$ Bn), 2018 - 2031
- 3.1.1. Key Highlights
  - 3.1.1.1. Bisphosphonates
  - 3.1.1.2. Parathyroid Hormone Therapy Drugs
  - 3.1.1.3. Calcitonin
  - 3.1.1.4. Selective Estrogen Receptors Modulators (SERMs)
  - 3.1.1.5. RANK Ligand Inhibitors
3.2. Global Osteoporosis Drugs Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
- 3.2.1. Key Highlights
  - 3.2.1.1. Retail Pharmacies
  - 3.2.1.2. Hospital Pharmacies
  - 3.2.1.3. Online Sales
3.3. Global Osteoporosis Drugs Market Outlook, by Region, Value (US$ Bn), 2018 - 2031
- 3.3.1. Key Highlights
  - 3.3.1.1. North America
  - 3.3.1.2. Europe
  - 3.3.1.3. Asia Pacific
  - 3.3.1.4. Latin America
  - 3.3.1.5. Middle East & Africa

4. North America Osteoporosis Drugs Market Outlook, 2018 - 2031

4.1. North America Osteoporosis Drugs Market Outlook, by Drug, Value (US$ Bn), 2018 - 2031
- 4.1.1. Key Highlights
  - 4.1.1.1. Bisphosphonates
  - 4.1.1.2. Parathyroid Hormone Therapy Drugs
  - 4.1.1.3. Calcitonin
  - 4.1.1.4. Selective Estrogen Receptors Modulators (SERMs)
  - 4.1.1.5. RANK Ligand Inhibitors
4.2. North America Osteoporosis Drugs Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
- 4.2.1. Key Highlights
  - 4.2.1.1. Retail Pharmacies
  - 4.2.1.2. Hospital Pharmacies
  - 4.2.1.3. Online Sales
4.3. North America Osteoporosis Drugs Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
- 4.3.1. Key Highlights
  - 4.3.1.1. U.S. Osteoporosis Drugs Market by Drug, Value (US$ Bn), 2018 - 2031
  - 4.3.1.2. U.S. Osteoporosis Drugs Market Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 4.3.1.3. Canada Osteoporosis Drugs Market by Drug, Value (US$ Bn), 2018 - 2031
  - 4.3.1.4. Canada Osteoporosis Drugs Market Distribution Channel, Value (US$ Bn), 2018 - 2031
- 4.3.2. BPS Analysis/Market Attractiveness Analysis

5. Europe Osteoporosis Drugs Market Outlook, 2018 - 2031

5.1. Europe Osteoporosis Drugs Market Outlook, by Drug, Value (US$ Bn), 2018 - 2031
- 5.1.1. Key Highlights
  - 5.1.1.1. Bisphosphonates
  - 5.1.1.2. Parathyroid Hormone Therapy Drugs
  - 5.1.1.3. Calcitonin
  - 5.1.1.4. Selective Estrogen Receptors Modulators (SERMs)
  - 5.1.1.5. RANK Ligand Inhibitors
5.2. Europe Osteoporosis Drugs Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
- 5.2.1. Key Highlights
  - 5.2.1.1. Retail Pharmacies
  - 5.2.1.2. Hospital Pharmacies
  - 5.2.1.3. Online Sales
5.3. Europe Osteoporosis Drugs Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
- 5.3.1. Key Highlights
  - 5.3.1.1. Germany Osteoporosis Drugs Market by Drug, Value (US$ Bn), 2018 - 2031
  - 5.3.1.2. Germany Osteoporosis Drugs Market Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 5.3.1.3. U.K. Osteoporosis Drugs Market by Drug, Value (US$ Bn), 2018 - 2031
  - 5.3.1.4. U.K. Osteoporosis Drugs Market Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 5.3.1.5. France Osteoporosis Drugs Market by Drug, Value (US$ Bn), 2018 - 2031
  - 5.3.1.6. France Osteoporosis Drugs Market Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 5.3.1.7. Italy Osteoporosis Drugs Market by Drug, Value (US$ Bn), 2018 - 2031
  - 5.3.1.8. Italy Osteoporosis Drugs Market Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 5.3.1.9. Turkey Osteoporosis Drugs Market by Drug, Value (US$ Bn), 2018 - 2031
  - 5.3.1.10. Turkey Osteoporosis Drugs Market Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 5.3.1.11. Russia Osteoporosis Drugs Market by Drug, Value (US$ Bn), 2018 - 2031
  - 5.3.1.12. Russia Osteoporosis Drugs Market Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 5.3.1.13. Rest of Europe Osteoporosis Drugs Market by Drug, Value (US$ Bn), 2018 - 2031
  - 5.3.1.14. Rest of Europe Osteoporosis Drugs Market Distribution Channel, Value (US$ Bn), 2018 - 2031
- 5.3.2. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Osteoporosis Drugs Market Outlook, 2018 - 2031

6.1. Asia Pacific Osteoporosis Drugs Market Outlook, by Drug, Value (US$ Bn), 2018 - 2031
- 6.1.1. Key Highlights
  - 6.1.1.1. Bisphosphonates
  - 6.1.1.2. Parathyroid Hormone Therapy Drugs
  - 6.1.1.3. Calcitonin
  - 6.1.1.4. Selective Estrogen Receptors Modulators (SERMs)
  - 6.1.1.5. RANK Ligand Inhibitors
6.2. Asia Pacific Osteoporosis Drugs Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
- 6.2.1. Key Highlights
  - 6.2.1.1. Retail Pharmacies
  - 6.2.1.2. Hospital Pharmacies
  - 6.2.1.3. Online Sales
6.3. Asia Pacific Osteoporosis Drugs Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
- 6.3.1. Key Highlights
  - 6.3.1.1. China Osteoporosis Drugs Market by Drug, Value (US$ Bn), 2018 - 2031
  - 6.3.1.2. China Osteoporosis Drugs Market Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 6.3.1.3. Japan Osteoporosis Drugs Market by Drug, Value (US$ Bn), 2018 - 2031
  - 6.3.1.4. Japan Osteoporosis Drugs Market Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 6.3.1.5. South Korea Osteoporosis Drugs Market by Drug, Value (US$ Bn), 2018 - 2031
  - 6.3.1.6. South Korea Osteoporosis Drugs Market Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 6.3.1.7. India Osteoporosis Drugs Market by Drug, Value (US$ Bn), 2018 - 2031
  - 6.3.1.8. India Osteoporosis Drugs Market Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 6.3.1.9. Southeast Asia Osteoporosis Drugs Market by Drug, Value (US$ Bn), 2018 - 2031
  - 6.3.1.10. Southeast Asia Osteoporosis Drugs Market Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 6.3.1.11. Rest of Asia Pacific Osteoporosis Drugs Market by Drug, Value (US$ Bn), 2018 - 2031
  - 6.3.1.12. Rest of Asia Pacific Osteoporosis Drugs Market Distribution Channel, Value (US$ Bn), 2018 - 2031
- 6.3.2. BPS Analysis/Market Attractiveness Analysis

7. Latin America Osteoporosis Drugs Market Outlook, 2018 - 2031

7.1. Latin America Osteoporosis Drugs Market Outlook, by Drug, Value (US$ Bn), 2018 - 2031
- 7.1.1. Key Highlights
  - 7.1.1.1. Bisphosphonates
  - 7.1.1.2. Parathyroid Hormone Therapy Drugs
  - 7.1.1.3. Calcitonin
  - 7.1.1.4. Selective Estrogen Receptors Modulators (SERMs)
  - 7.1.1.5. RANK Ligand Inhibitors
7.2. Latin America Osteoporosis Drugs Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
- 7.2.1. Key Highlights
  - 7.2.1.1. Retail Pharmacies
  - 7.2.1.2. Hospital Pharmacies
  - 7.2.1.3. Online Sales
7.3. Latin America Osteoporosis Drugs Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
- 7.3.1. Key Highlights
  - 7.3.1.1. Brazil Osteoporosis Drugs Market by Drug, Value (US$ Bn), 2018 - 2031
  - 7.3.1.2. Brazil Osteoporosis Drugs Market Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 7.3.1.3. Mexico Osteoporosis Drugs Market by Drug, Value (US$ Bn), 2018 - 2031
  - 7.3.1.4. Mexico Osteoporosis Drugs Market Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 7.3.1.5. Argentina Osteoporosis Drugs Market by Drug, Value (US$ Bn), 2018 - 2031
  - 7.3.1.6. Argentina Osteoporosis Drugs Market Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 7.3.1.7. Rest of Latin America Osteoporosis Drugs Market by Drug, Value (US$ Bn), 2018 - 2031
  - 7.3.1.8. Rest of Latin America Osteoporosis Drugs Market Distribution Channel, Value (US$ Bn), 2018 - 2031
- 7.3.2. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Osteoporosis Drugs Market Outlook, 2018 - 2031

8.1. Middle East & Africa Osteoporosis Drugs Market Outlook, by Drug, Value (US$ Bn), 2018 - 2031
- 8.1.1. Key Highlights
  - 8.1.1.1. Bisphosphonates
  - 8.1.1.2. Parathyroid Hormone Therapy Drugs
  - 8.1.1.3. Calcitonin
  - 8.1.1.4. Selective Estrogen Receptors Modulators (SERMs)
  - 8.1.1.5. RANK Ligand Inhibitors
8.2. Middle East & Africa Osteoporosis Drugs Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
- 8.2.1. Key Highlights
  - 8.2.1.1. Retail Pharmacies
  - 8.2.1.2. Hospital Pharmacies
  - 8.2.1.3. Online Sales
8.3. Middle East & Africa Osteoporosis Drugs Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
- 8.3.1. Key Highlights
  - 8.3.1.1. GCC Osteoporosis Drugs Market by Drug, Value (US$ Bn), 2018 - 2031
  - 8.3.1.2. GCC Osteoporosis Drugs Market Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 8.3.1.3. South Africa Osteoporosis Drugs Market by Drug, Value (US$ Bn), 2018 - 2031
  - 8.3.1.4. South Africa Osteoporosis Drugs Market Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 8.3.1.5. Egypt Osteoporosis Drugs Market by Drug, Value (US$ Bn), 2018 - 2031
  - 8.3.1.6. Egypt Osteoporosis Drugs Market Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 8.3.1.7. Nigeria Osteoporosis Drugs Market by Drug, Value (US$ Bn), 2018 - 2031
  - 8.3.1.8. Nigeria Osteoporosis Drugs Market Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 8.3.1.9. Rest of Middle East & Africa Osteoporosis Drugs Market by Drug, Value (US$ Bn), 2018 - 2031
  - 8.3.1.10. Rest of Middle East & Africa Osteoporosis Drugs Market Distribution Channel, Value (US$ Bn), 2018 - 2031
- 8.3.2. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

9.1. Product vs Distribution Channel Heatmap
9.2. Manufacturer vs Distribution Channel Heatmap
9.3. Company Market Share Analysis, 2023
9.4. Competitive Dashboard
9.5. Company Profiles
- 9.5.1. Eli Lilly and Company
  - 9.5.1.1. Company Overview
  - 9.5.1.2. Product Portfolio
  - 9.5.1.3. Financial Overview
  - 9.5.1.4. Business Strategies and Development
- 9.5.2. F. Hoffmann-La Roche Ltd.
  - 9.5.2.1. Company Overview
  - 9.5.2.2. Product Portfolio
  - 9.5.2.3. Financial Overview
  - 9.5.2.4. Business Strategies and Development
- 9.5.3. Merck & Co, Inc.
  - 9.5.3.1. Company Overview
  - 9.5.3.2. Product Portfolio
  - 9.5.3.3. Financial Overview
  - 9.5.3.4. Business Strategies and Development
- 9.5.4. Novartis AG
  - 9.5.4.1. Company Overview
  - 9.5.4.2. Product Portfolio
  - 9.5.4.3. Financial Overview
  - 9.5.4.4. Business Strategies and Development
- 9.5.5. Amgen, Inc.
  - 9.5.5.1. Company Overview
  - 9.5.5.2. Product Portfolio
  - 9.5.5.3. Financial Overview
  - 9.5.5.4. Business Strategies and Development
- 9.5.6. Novo Nordisk A/S
  - 9.5.6.1. Company Overview
  - 9.5.6.2. Product Portfolio
  - 9.5.6.3. Financial Overview
  - 9.5.6.4. Business Strategies and Development
- 9.5.7. Actavis plc
  - 9.5.7.1. Company Overview
  - 9.5.7.2. Product Portfolio
  - 9.5.7.3. Financial Overview
  - 9.5.7.4. Business Strategies and Development
- 9.5.8. Pfizer, Inc.
  - 9.5.8.1. Company Overview
  - 9.5.8.2. Product Portfolio
  - 9.5.8.3. Financial Overview
  - 9.5.8.4. Business Strategies and Development
- 9.5.9. GlaxoSmithKline plc
  - 9.5.9.1. Company Overview
  - 9.5.9.2. Product Portfolio
  - 9.5.9.3. Financial Overview
  - 9.5.9.4. Business Strategies and Development
- 9.5.10. Teva Pharmaceutical Industries Ltd
  - 9.5.10.1. Company Overview
  - 9.5.10.2. Product Portfolio
  - 9.5.10.3. Financial Overview
  - 9.5.10.4. Business Strategies and Development
- 9.5.11. Enzene Biosciences Ltd
  - 9.5.11.1. Company Overview
  - 9.5.11.2. Product Portfolio
  - 9.5.11.3. Financial Overview
  - 9.5.11.4. Business Strategies and Development
- 9.5.12. Theramex
  - 9.5.12.1. Company Overview
  - 9.5.12.2. Product Portfolio
  - 9.5.12.3. Financial Overview
  - 9.5.12.4. Business Strategies and Development

10. Appendix

10.1. Research Methodology
10.2. Report Assumptions
10.3. Acronyms and Abbreviations